|Videos|March 6, 2023
Considerations for the Treatment of Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia
Best practices and special considerations for effective therapy selection and sequencing in the relapsed/refractory ALL setting.
Advertisement
Episodes in this series
Advertisement
Related to this article
Sagar Lonial, MD, FACP, FASCO, and Sikander Ailawadhi, MD, discuss the investigation of cemsidomide in relapsed/refractory multiple myeloma.
Mayo Clinic Study Estimates Cancer Risk in Patients With Pancreatic Cysts, Advancing Early Detection
Mayo Clinic researchers have estimated the risk that pancreatic cysts with worrisome or high-risk features will progress to pancreatic cancer or advanced precancerous changes.
The oral pan-RAS molecular glue ERAS-0015 has received FDA fast track designation for the management of metastatic pancreatic adenocarcinoma.
The MHLW approval covers all lines of therapy, including first-line use, in unresectable advanced or recurrent HER2-mutant NSCLC.
The FDA set a target action date of February 2027 for the dostarlimab-gxly sBLA in dMMR/MSI-H locally advanced rectal cancer.
The European Commission approved sacituzumab govitecan plus pembrolizumab for treatment-naive, PD-L1-positive metastatic triple-negative breast cancer.
R. Lor Randall, MD, FACS, discusses what’s next for TGCT treatment and the most important developments to come out of 2026 TGCT Master Workshop.
Teclistamab-based induction generated a 91.8% MRD-negative complete response rate with a manageable safety profile in multiple myeloma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to Pan-RAS Molecular Glue ERAS-0015 for Metastatic Pancreatic Adenocarcinoma
2
Darlifarnib Plus Cabozantinib Displays Early Signals of Safety and Efficacy in RCC
3
The OncFive: Top Oncology Articles for the Week of 8/16
4
Five Under 5: Top Oncology Videos for the Week of 8/16
5